Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:VRTX) revealed 9 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $415,070, and 3 were calls, valued at $343,350.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $480.0 to $500.0 for Vertex Pharmaceuticals over the recent three months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Vertex Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Vertex Pharmaceuticals's significant trades, within a strike price range of $480.0 to $500.0, over the past month.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
VRTX | PUT | SWEEP | BULLISH | 01/17/25 | $30.6 | $29.5 | $29.5 | $500.00 | $200.6K | 42 | 115 |
VRTX | CALL | TRADE | BULLISH | 01/17/25 | $34.0 | $33.1 | $34.0 | $500.00 | $170.0K | 464 | 56 |
VRTX | CALL | SWEEP | BEARISH | 10/18/24 | $14.7 | $14.3 | $14.3 | $500.00 | $143.0K | 392 | 100 |
VRTX | PUT | SWEEP | BULLISH | 01/17/25 | $30.6 | $29.6 | $29.7 | $500.00 | $74.2K | 42 | 36 |
VRTX | PUT | SWEEP | BEARISH | 01/17/25 | $22.9 | $21.5 | $22.9 | $480.00 | $41.2K | 1.1K | 28 |
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Having examined the options trading patterns of Vertex Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
5 market experts have recently issued ratings for this stock, with a consensus target price of $537.8.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from Benzinga Pro.
Posted In: VRTX